| ［1］ |
李吉, 何琳, 谢红付, 等. 玫瑰痤疮分型再认识［J］. 实用医院临床杂志, 2015,（2）:1⁃2. doi: 10.3969/j.issn.1672⁃6170.2015. 02.001.<br />
|
| ［2］ |
Wilkin J, Dahl M, Detmar M, et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea［J］. J Am Acad Dermatol, 2004,50（6）:907⁃912. doi: 10.1016/j.jaad.2004.01. 048.<br />
|
| ［3］ |
Robinson T. On acne rosacea［J］. Br Med J, 1885,1（1255）:124⁃126.<br />
|
| ［4］ |
Turgut EA, Gurel MS, Koku Aksu AE, et al. Demodex mites in acne rosacea: reflectance confocal microscopic study［J］. Australas J Dermatol, 2017,58（2）:e26⁃e30. doi: 10.1111/ajd. 12452.<br />
|
| ［5］ |
Maibach HI. The cosmetic intolerance syndrome［J］. Ear Nose Throat J, 1987,66（1）:29⁃33.<br />
|
| ［6］ |
何黎, 郑捷, 马慧群, 等. 中国敏感性皮肤诊治专家共识［J］. 中国皮肤性病学杂志, 2017,31（1）:1⁃4.<br />
|
| ［7］ |
中国医师协会皮肤科医师分会皮肤美容亚专业委员会. 中国玫瑰痤疮诊疗专家共识（2016）［J］. 中华皮肤科杂志, 2017,50（3）:156⁃161. doi: 10.3760/cma.j.issn.0412⁃4030.2017.03.002.<br />
|
| ［8］ |
Akilov OE, Kazanceva SV, Vlasova IA. Particular features of immune response after invasion of different species of human Demodex mites［J］. Russ J Immunol, 2001,6（4）:399⁃404.<br />
|
| ［9］ |
Kanitakis J, Al⁃Rifai I, Faure M, et al. Demodex mites of human skin express Tn but not T （Thomsen⁃Friedenreich） antigen immunoreactivity［J］. J Cutan Pathol, 1997,24（7）:454⁃455.<br />
|
| ［10］ |
Jarmuda S, McMahon F, Zaba R, et al. Correlation between serum reactivity to Demodex⁃associated Bacillus oleronius proteins, and altered sebum levels and Demodex populations in erythematote⁃langiectatic rosacea patients［J］. J Med Microbiol, 2014,63（Pt 2）:258⁃262. doi: 10.1099/jmm.0.065136⁃0.<br />
|
| ［11］ |
Jarmuda S, O′Reilly N, Zaba R, et al. Potential role of Demodex mites and bacteria in the induction of rosacea［J］. J Med Microbiol, 2012,61（Pt 11）:1504⁃1510. doi: 10.1099/jmm.0. 048090⁃0.<br />
|
| ［12］ |
Allen JE, Sutherland TE, Rückerl D. IL⁃17 and neutrophils: unexpected players in the type 2 immune response［J］. Curr Opin Immunol, 2015,34: 99⁃106. doi: 10.1016/j.coi.2015.03.001.<br />
|
| ［13］ |
McMahon F, Banville N, Bergin DA, et al. Activation of neutrophils via IP3 pathway following exposure to Demodex⁃associated bacterial proteins［J］. Inflammation, 2016,39（1）:425⁃433. doi: 10.1007/s10753⁃015⁃0264⁃4.<br />
|
| ［14］ |
Ayres S, AYRES S. Demodectic eruptions （demodicidosis） in the human. 30 years′ experience with 2 commonly unrecognized entities: pityriasis folliculorum （Demodex） and acne rosacea （Demodex type）［J］. Arch Dermatol, 1961,83: 816⁃827.<br />
|
| ［15］ |
Porta GCA. Demodex folliculorum: its association with oily skin surface rather than rosacea lesions［J］. Int J Dermatol, 2015,54（1）:e14⁃17. doi: 10.1111/ijd.12398.<br />
|
| ［16］ |
Turgut EA, Gurel MS, Koku AAE, et al. Reflectance confocal microscopy vs. standardized skin surface biopsy for measuring the density of Demodex mites［J］. Skin Res Technol, 2014,20（4）:435⁃439. doi: 10.1111/srt.12137.<br />
|
| ［17］ |
Chang YS, Huang YC. Role of Demodex mite infestation in rosacea: a systematic review and meta⁃analysis［J］. J Am Acad Dermatol, 2017,77（3）:441⁃447.e6. doi: 10.1016/j.jaad.2017. 03.040.<br />
|
| ［18］ |
闫慧敏, 赵惠娟, 姜薇. 高通量测序分析红斑期酒渣鼻患者与健康人面部皮肤微生物的分布差异［J］. 中国皮肤性病学杂志, 2016,30（10）:991⁃997. doi: 10.13735/j.cjdv.1001⁃7089. 201602060.<br />
|
| ［19］ |
Del Rosso JQ. Advances in understanding and managing rosacea: part 2: the central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea advances in understanding and managing rosacea: part 2: the central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea［J］. J Clin Aesthet Dermatol, 2012,5（3）:26⁃36.<br />
|
| ［20］ |
Kanada KN, Nakatsuji T, Gallo RL. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein⁃related peptidases and activation of cathelicidin［J］. J Invest Dermatol, 2012,132（5）:1435⁃1442. doi: 10.1038/jid.2012.14.<br />
|
| ［21］ |
Del RJQ, Schlessinger J, Werschler P. Comparison of anti⁃inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea［J］. J Drugs Dermatol, 2008,7（6）:573⁃576.<br />
|
| ［22］ |
Del RJQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti⁃inflammatory dose doxycycline （40⁃mg doxycycline, USP capsules） administered once daily for treatment of rosacea［J］. J Am Acad Dermatol, 2007,56（5）:791⁃802. doi: 10.1016/j.jaad.2006.11.021.<br />
|
| ［23］ |
Webster GF. An open⁃label, community⁃based, 12⁃week assessment of the effectiveness and safety of monotherapy with doxycycline 40 mg （30⁃mg immediate⁃release and 10⁃mg delayed⁃release beads） ［J］. Cutis, 2010,86（5 Suppl）:7⁃15.<br />
|
| ［24］ |
Christiansen K. Fusidic acid non⁃antibacterial activity［J］. Int J Antimicrob Agents, 1999,12 Suppl 2: S73⁃78.<br />
|
| ［25］ |
Bendtzen K, Diamant M, Faber V. Fusidic acid, an immuno⁃suppressive drug with functions similar to cyclosporin A［J］. Cytokine, 1990,2（6）:423⁃429.<br />
|
| ［26］ |
仲少敏, 郭建美, 陶荣, 等. 夫西地酸乳膏对小鼠急性皮肤屏障损伤引起炎症反应的抑制作用［J］. 中华皮肤科杂志, 2014,47（12）:864⁃867. doi: 10.3760/cma.j.issn.0412⁃4030.2014.12.009.<br />
|
| ［27］ |
Seal DV, Wright P, Ficker L, et al. Placebo controlled trial of fusidic acid gel and oxytetracycline for recurrent blepharitis and rosacea［J］. Br J Ophthalmol, 1995,79（1）:42⁃45.<br />
|
| ［28］ |
Badieyan ZS, Hoseini SS. Improvement of rosacea during acyclovir treatment: a case report［J］. Am J Clin Dermatol, 2017,18（6）:845⁃846. doi: 10.1007/s40257⁃017⁃0315⁃8.<br />
|
| ［29］ |
郝飞, 宋志强. 提高对玫瑰痤疮的认识水平［J］. 中华皮肤科杂志, 2017,50（3）:153⁃155. doi: 10.3760/cma.j.issn.0412⁃4030. 2017.03.001.<br />
|
| ［30］ |
Hofer T. Continuous ′microdose′ isotretinoin in adult recalcitrant rosacea［J］. Clin Exp Dermatol, 2004,29（2）:204⁃205.<br />
|
| ［31］ |
Uslu M, Şavk E, Karaman G, et al. Rosacea treatment with intermediate⁃dose isotretinoin: follow⁃up with erythema and sebum measurements［J］. Acta Derm Venereol, 2012,92（1）:73⁃77. doi: 10.2340/00015555⁃1204.<br />
|
| ［32］ |
Millikan L. The proposed inflammatory pathophysiology of rosacea: implications for treatment［J］. Skinmed, 2003,2（1）:43⁃47.<br />
|
